SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing a surge in investor interest and trading volume driven by persistent market speculation regarding potential M&A activity. While retail sentiment remains highly divided between long-term holders hopeful for a buyout premium and skeptics wary of the lack of official confirmation, the unusual after-hours price action has prompted significant discussion across community forums.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and trending attention as retail investors speculate on its high-profile private company portfolio, including holdings like SpaceX and OpenAI. The stock is seeing heavy trading activity and community discussion centered on the impact of a six-month lockup period, which has limited available float and fueled intense debate over its valuation relative to its underlying net asset value.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE has emerged as a trending meme coin, triggering a polarized debate among traders over whether it represents a legitimate high-growth asset or a blatant pump-and-dump scheme. While some investors are actively accumulating the token in hopes of repeating past meme coin rallies, others are dismissing the project as a low-quality scam with unsustainable price action.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market volatility remains high as traders react to conflicting reports regarding U.S.-Iran diplomatic talks, with many observers expressing skepticism toward official announcements given the recent escalation in energy infrastructure attacks. Community discussions are dominated by concerns over geopolitical instability, accusations of market manipulation by political figures, and the potential for a broader energy crisis impacting long-term economic stability.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is seeing increased market attention driven by a combination of housing supply fluctuations, evolving macro rate expectations, and integration with generative AI tools like ChatGPT. Community members remain actively divided, with some highlighting the stock as an undervalued opportunity for long-term recovery, while others express caution regarding ongoing antitrust litigation and intensified competition from tech giants entering the real estate listings space.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is gaining momentum following a successful mission launch and ongoing investor optimism surrounding its diversified defense and lunar business segments. Community members are closely tracking the stock's performance in light of upcoming guidance and potential catalysts like the broader expansion of the commercial space economy.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh potential catalysts from the anticipated Schedule 3 rescheduling of cannabis against ongoing skepticism regarding the company's aggressive acquisition strategy and its transition into the beverage sector. The community is actively debating the timing and impact of federal regulatory shifts, with many retail investors expressing frustration over long-term performance while others remain hopeful for a short-squeeze driven by high short interest and sector-wide volatility.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major management shake-up that saw long-time CEO Peter Greenleaf replaced by Board Chair Kevin Tang, who has notably elected to forgo all compensation. The community is actively discussing the potential for a rapid sale or buyout of the company, with many retail investors expressing relief at the removal of former leadership and optimism regarding Tang's alignment with shareholder value.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is gaining momentum as investors closely monitor weekly prescription data for its fibromyalgia drug, Tonmya, which is showing signs of early adoption and patient refill retention. Community discussion remains heavily focused on the company's recent leadership insider purchases, anticipation for upcoming quarterly results, and strategic speculation regarding potential partnerships or buyouts within the CNS sector.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors aggressively position themselves ahead of the company's earnings release, with heavy community speculation focusing on potential updates regarding NASA's Lunar Terrain Vehicle contract. Sentiment remains divided between those betting on transformative revenue growth and a potential short squeeze, and those highlighting the execution risks inherent in the aerospace sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $761,676.24 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,972 shares of the firm's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total value of $761,676.24. Following the completion of the transaction, the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Jeffrey Farrow Sells 2,111 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Jeffrey Farrow sold 2,111 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total transaction of $146,545.62. Following the transaction, the insider owned 47,635...

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 2,186 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Jeffrey Farrow sold 2,186 shares of the business's stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $146,462.00. Following the transaction, the insider...

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 2,133 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Jeffrey Farrow sold 2,133 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $68.71, for a total transaction of $146,558.43. Following the completion of the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 390 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 390 shares of the firm's stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $26,130.00. Following the sale, the insider directly owned...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 375 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 375 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total transaction of $26,032.50. Following the transaction...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,041.09 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 379 shares of the company's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total transaction of $26,041.09. Following the completion of the...

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 4,029 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne Whitfield sold 4,029 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total value of $279,693.18. Following the transaction, the insider owned...

Dianne Whitfield Sells 4,071 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne Whitfield sold 4,071 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $279,718.41. Following the transaction, the insider owned 39,202...

Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells $283,428.75 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 4,125 shares of the stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $68.71, for a total value of $283,428.75. Following the transaction, the general counsel...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TARS News

TARSTarsus Pharmaceuticals Inc